On February 2, 2023 Ashvattha Therapeutics ("Ashvattha"), a clinical-stage company leveraging its nanomedicine technology, hydroxyl dendrimers (HDs), to develop a new class of precision medicines, reported that the Company will provide a corporate overview at two upcoming investor conferences (Press release, Ashvattha Therapeutics, FEB 2, 2023, View Source [SID1234626758]). The corporate overview will highlight the company’s innovative approach to precision nanomedicine through its proprietary hydroxyl dendrimer therapies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details for the presentations are as follows:

2023 BIO CEO & Investor Conference
Date: Monday, February 6, 2023
Time: 2:15 PM ET
Location: Palace Room, Marriott Marquis, New York, and virtual
Biocom California’s 13th Annual Global Life Science Partnering & Investor Conference
Date: Wednesday, March 1, 2023
Time: 4:09 PM PT
Location: Charles Fries Room, The Lodge at Torrey Pines, La Jolla, California
Jeffrey Cleland, Ph.D., Chairman, Chief Executive Officer, and President of Ashvattha will be available for one-on-one meetings onsite with registered attendees.